Antares Pharma Announces Update to QuickShot Testosterone

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Antares Pharma Announces Update to QuickShot Testosterone Clinical Program

EWING, N.J., June 01, 2016 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS ) today announced that the last patient has completed treatment in a dose-blinded, multiple-dose, concentration controlled 26-week safety and pharmacokinetic phase 3 study of QuickShot® Testosterone (QS T) administered subcutaneously once each week to adult males with hypogonadism.  The study, QST-15-005 included a screening phase, a titration phase and a treatment phase for evaluation of safety and tolerability assessments, including laboratory assessments, adverse events and injection site assessments.  The study was conducted to help ensure that we satisfy the U.S. Food and Drug Administration’s recommendation that we have a safety database of approximately 350 subjects exposed to QS T in total with approximately 200 subjects exposed for six months and approximately 100 subjects exposed for a year.

“We are very excited to announce that the last patient has completed treatment in our phase 3 supplemental safety study of QuickShot testosterone,” stated Robert F. Apple, President and Chief Executive Officer. “With this study now concluded, we will combine these data with the previously announced positive pharmacokinetic and safety data from the QST-13-003 study for inclusion into our New Drug Application, with a filing goal of later this year or in early 2017.  We plan to work closely with the Food and Drug Administration on the potential approval of this novel approach to treating hypogonadism.”

About Antares Pharma

Antares Pharma focuses on self-administered parenteral pharmaceutical products. The Company’s product, OTREXUP™ (methotrexate) injection for subcutaneous use, is approved in the U.S. for the treatment of adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant psoriasis. Antares Pharma is also developing QuickShot ® Testosterone for testosterone replacement therapy, and has recently received a therapeutically equivalent approval from the U.S. Food and Drug Administration for VIBEX ® Sumatriptan USP for the acute treatment of migraine and cluster headache.  The Company's technology platforms include VIBEX ® disposable auto injectors, disposable multi-use pen injectors and reusable needle-free injectors. Antares Pharma has a multi-product deal with Teva Pharmaceutical Industries, Ltd. that includes VIBEX ® epinephrine, exenatide multi-dose pen, and teriparatide multi-dose pen.  Our reusable needle-free injector for use with human growth hormone (hGH) is sold worldwide by Ferring B.V.  The Company is also working with AMAG Pharmaceuticals on a subcutaneous method of administering Makena, a progesterone product indicated for use in lowering the risk of pre-term birth.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described.  Factors that may cause such differences include, but are not limited to: the timing and results of the phase 3 studies for QuickShot ® Testosterone (QS T) and acceptance of the data by the U.S. Food and Drug Administration (“FDA”); the timing and Company’s ability to successfully complete a New Drug Application (“NDA”) for QS T,  acceptance of the NDA for QS T by the FDA and approval of the same by the FDA; Teva’s ability to adequately and timely respond to the Complete Response Letter received from the FDA for the VIBEX ® epinephrine pen Abbreviated New Drug Application (“ANDA”) and approval by the FDA of the same, the timing and therapeutic equivalence rating thereof, and any future purchase orders and revenue pre or post FDA approval; the timing of the launch of VIBEX ® Sumatriptan Injection USP and the amount of revenue from the same; the outcome of the pending patent litigation between Teva Pharmaceutical Industries, Ltd. (Teva) and Eli Lilly and Company regarding the Teriparatide multi-dose pen; the timing and approval, if any, by the FDA of Teva’s ANDA for the Teriparatide multi-dose pen and any future revenue resulting therefrom; the outcome of the pending patent litigation between  Teva and AstraZeneca regarding the Exenatide multi-dose pen; FDA action with respect to Teva’s ANDA filed for the Exenatide pen and future revenue from the same; continued growth of prescriptions and sales of OTREXUP™;  the timing and results of the development project with AMAG Pharmaceuticals for an auto injector for Makena; the timing and results of research projects, clinical trials, and product candidates in development; actions by the FDA or other regulatory agencies with the respect to the Company’s products or product candidates of its partners; continued growth in product, development, licensing and royalty revenue; the Company’s ability to obtain financial and other resources for its research, development, clinical, and commercial activities and other statements regarding matters that are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as ''may'', ''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'', ''anticipate'', ''believe'', ''estimate'', ''predict'', ''potential'', ''seem'', ''seek'', ''future'', ''continue'', or ''appear'' or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2015, and in the Company's other periodic reports and filings with the Securities and Exchange Commission.  The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.

Contacts: Jack Howarth Vice President, Corporate Affairs 609-359-3016 jhowarth@antarespharma.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Markel's $2.5 Billion Buyback Adds Capital Flexibility

Updated Category News Views 66

A Large Checkbook, Not a Purchase Order Markel just handed management another $2.5 billion of repurchase firepower, and that deserves attention without the usual buyback cheerleading. The Board approved an increase to the existing authorization on November 18, 2026. That is a meaningful capital-allocation signal from a company built around specialty insurance,...

Continue Reading
MIND Takes Its Copilot Security Bet Across Microsoft 365

Updated Category News Views 59

Copilot’s promise gets a lot less charming the minute confidential files start wandering around unchecked. That is the knot MIND is trying to untie with its expanded, generally available integrations across Microsoft Copilot, Microsoft 365, Purview, Teams, SharePoint, OneDrive, Edge and Exchange. The Seattle data-loss-prevention company announced the collaboration on...

Continue Reading
Vector's Peptide Pact Needs Proof Before Any Payday

Updated Category News Views 174

A famous orthopedic name can open doors, but it cannot manufacture clinical evidence. That is the plain reality behind Vector Science and Therapeutics' new collaboration with the Andrews Research & Education Foundation. Dr. James Andrews carries enormous credibility in sports medicine, earned across more than five decades of work. For Vector, that association matters. For...

Continue Reading
BLLN Faces Fresh Questions After Short-Seller Report

Updated Category News Views 33

A six-percent air pocket is one thing; a disclosure mismatch is another beast entirely. BillionToOne shares fell on November 18 after short-seller Fuzzy Panda Research alleged the company had not disclosed meaningful regulatory scrutiny, including an alleged Tennessee matter in which regulators suspected fraud in 2024. That is an allegation from a short seller, not a...

Continue Reading
Perform.AI Tests Whether Stores Can Sell to Agents

Updated Category News Views 85

Shopping bots are about to become one more fussy customer standing in the aisle, except this one reads machine-facing files, rejects broken checkout steps, and does not care how pretty the homepage looks. Perform.AI has launched a free UCP and ACP Readiness Checker aimed at online retailers that need to know whether AI agents can find products, purchase them, and follow...

Continue Reading
Four Pending Deals Put Shareholder Terms Under Scrutiny

Updated Category News Views 101

Four corporate transactions landed under a legal microscope on November 18, and that is never background noise for shareholders trying to judge whether the paperwork matches the price. Halper Sadeh LLC says it is investigating proposed deals involving WaFd, Personalis, Dana and Baldwin Group for possible federal securities-law violations and/or fiduciary-duty breaches....

Continue Reading
Harbour BioMed's LET003 Gets China's IND Green Light

Updated Category News Views 64

Muscle loss has become the awkward fact sitting beside every blockbuster obesity headline. Harbour BioMed's Nov. 18 announcement that China's National Medical Products Administration accepted its IND application for LET003 matters because the company is aiming directly at that problem: losing fat without giving away too much lean mass along the way. Acceptance Opens a...

Continue Reading
Cadence Marks $2.7 Million for St. Jude Family Care

Updated Category News Views 112

Small Wheels, Serious Purpose Tiny tricycles, flour-dusted bake-sale tables, and family pledges have pushed Cadence Education’s St. Jude partnership to $2.7 million since 2018. That number is not a flashy balance-sheet item, nor should anybody try to dress it up as one. It is the accumulated result of school communities showing up year after year, and in a sector built...

Continue Reading
Hot Dog Marketing Makes a Serious Public-Sector Push

Updated Category News Views 25

Five well-connected Central Texas names can tell you plenty about where an agency intends to hunt next. Hot Dog Marketing's Nov. 18 move is not some shiny rebrand with confetti tossed at the wall. The Austin-based firm is putting strategic communications beside its established marketing work and bringing in a five-member Strategic Advisory Council aimed squarely at...

Continue Reading
Sysco's Northern California Labor Deal Gets Bigger

Updated Category News Views 56

One hundred forty-four drivers may not rattle a giant food distributor by themselves, but labor agreements have a habit of growing legs. Sysco's Northern California and Nevada regional contract has added members from Teamsters Locals 386 and 431, bringing its coverage above 1,100 workers. For investors watching Sysco, this is less about one afternoon's headline and more...

Continue Reading

Top 5 Most Recently Viewed Articles

KLA Corporation Announces Quarterly Cash Dividend for Shareholders

Updated Category News Views 118

KLA Corporation Declares Cash Dividend for Investors The KLA Corporation (NASDAQ: KLAC), renowned for its innovation within the electronics industry, has taken a significant step to reward its shareholders. The Board of Directors recently announced a quarterly cash dividend of $1.90 per share. This decision reflects KLA's commitment to delivering value to its investors...

Continue Reading
Peptone Market Growth Projected to Reach $240.5 Million

Updated Category News Views 170

Overview of the Peptone Market The peptone market is on an impressive growth trajectory, expected to reach an estimated value of $240.5 million by 2035. This significant growth is attributed to a compound annual growth rate (CAGR) of 4.2% from 2024 to 2035. The driving forces behind this trend include rising demand in biopharmaceutical production, the application of...

Continue Reading
Roch Dog Introduces Innovative AI Certification for Hotels

Updated Category News Views 310

Revolutionizing Pet-Friendly Travel with AI Roch Dog, an NVIDIA Inception startup, has disrupted the hotel industry by launching the first AI certification engine focused on pet-friendly hotels. This innovative platform streamlines the processes of assessment, certification, ranking, and review of hotels based on their pet-friendly offerings. With a commitment to...

Continue Reading
Major Holdings Update from Wellington Management Group LLP

Updated Category News Views 198

Understanding Major Holdings Notifications In the world of finance and investments, major holdings notifications play a vital role in maintaining transparency and trust among investors and stakeholders. This process helps companies keep everyone informed about significant changes in ownership, which can impact decision-making and share prices. Today, we will delve into...

Continue Reading
German Housing Market Shows Signs of Recovery Amid Declines

Updated Category News Views 148

Recent Trends in the German Housing Market In the second quarter, Germany saw a significant drop in residential property prices, averaging a decrease of 2.6% compared to last year. However, a new report from the federal statistics office reveals some encouraging signs that suggest the market may be stabilizing. Quarterly Growth Despite Yearly Declines While the annual...

Continue Reading